Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

FARAFARA Cure FA

Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia

BACKGROUND:

Erythropoietin (EPO) derivatives have been found to increase frataxin levels in Friedreich's ataxia (FRDA) in vitro. This multicenter, double-blind, placebo-controlled, phase II clinical trial aimed to evaluate the safety and tolerability of Lu AA24493 (carbamylated EPO; CEPO).

Read More: Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia


About the Author

Jen Farmer

Jen Farmer

Executive Director

SHARE

FacebookTwitterLinkedInYoutube
Event H.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News